Eli Lilly, Novo to lead weight loss drug market: JPMorgan
Fotolia/iStock via Getty Images JPMorgan recently raised its projections for weight loss drugs, expecting the drug category known as GLP-1 agonists to bring over $100B in annual sales by 2030 in a duopoly controlled by Novo Nordisk…